Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classification

2 May 2024

Abstract excerpt

Background: The 2022 World Health Organization (WHO) classification of pituitary neuroendocrine tumour (PitNET) supersedes the previous one in 2017 and further consolidates the role of transcription factors (TF) in the diagnosis of PitNET. Here, we investigated the clinical utility of the 2022 WHO classification, as compared to that of 2017, in a cohort of patients with non-functioning PitNET (NF-PitNET)....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Growth Hormone and Insulin-like Growth Factors
Share to Neuroendocrine Tumor Research Advances
Share to Pituitary Gland Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38756997
DOI: 10.3389/fendo.2024.1368944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A clinicopathological study of non-functioning pituitary neuroendocrine tumours using the World Health Organization 2022 classificationPMID 38756997Read ↗

Transcription Factor–Based Classification of Pituitary Neuroendocrine Tumors: Practical Immunohistochemical Algorithms, Molecular Correlates, and Diagnostic Challenges in the 5th WHO EraSemantic proximity Read ↗

Validation of a Clinicopathological Classification for Predicting Outcomes of Pituitary Tumours: Retrospective Cohort Study in a Pituitary Tumour Centre of Excellence, 2013–2023Semantic proximity Read ↗

Annotation of pituitary neuroendocrine tumors with genome-wide expression analysisSemantic proximity Read ↗

Clinical integration and application of the 2022 WHO pituitary tumor classificationSemantic proximity Read ↗

Pangenomic Classification of Pituitary Neuroendocrine Tumors.Semantic proximity Read ↗

Splicing diversity enhances the molecular classification of pituitary neuroendocrine tumorsSemantic proximity Read ↗

How Valuable Is the RT-qPCR of Pituitary-Specific Transcription Factors for Identifying Pituitary Neuroendocrine Tumor Subtypes According to the New WHO 2017 Criteria?Semantic proximity Read ↗

Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor CellsSemantic proximity Read ↗

Transcription factor immunohistochemistry in the diagnosis of pituitary tumoursSemantic proximity Read ↗

Single-cell sequencing identifies differentiation-related markers for molecular classification and recurrence prediction of PitNETSemantic proximity Read ↗

Transcriptomic perspective on acromegaly- related PIT-1/SF-1 positive pituitary tumorsSemantic proximity Read ↗

Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.